– Best-in-class profile demonstrated with repeat dosing across dose levels – – Antitumor activity observed…
– ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects…
Results from two parallel trials show Cosentyx® (secukinumab) demonstrated superior efficacy vs placebo with statistically…
LinkDaddy has announced a new update to its digital marketing service to help businesses increase…
IRVINE, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) — We know how important it is to…
Superior Revenue Growth Earns Coveted Recognition Among America’s Fastest-Growing Companies DENVER–(BUSINESS WIRE)–#alternativeenergy—Solar America, the leading…
PORTLAND, Ore., Sept. 09, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF)…
NEW YORK–(BUSINESS WIRE)–#KBRA–On September 8, 2022, KBRA assigned a long-term rating of AAA, with a…
NEW YORK–(BUSINESS WIRE)–KKR Income Opportunities Fund (the “Fund”) (NYSE: KIO) announced today that the Q2…
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–Viad Corp (NYSE: VVI), a leading global provider of extraordinary experiences, including hospitality…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA assigns ratings to three classes of additional Series 2022-1 Notes (“CPC 2022-1”)…
PowerSchool Unified Classroom®, Unified Talent™ and Naviance selected as winners in primary and secondary categories…
New York, NY, and Tel Aviv, ISRAEL, Sept. 09, 2022 (GLOBE NEWSWIRE) — via NewMediaWire…
FAIRFIELD, N.J.–(BUSINESS WIRE)–DLA LLC (DLA), a leading provider of internal audit, accounting advisory, and corporate…
Presentation on September 13, 2022, at 11:00 a.m. ET LOS ANGELES–(BUSINESS WIRE)–$CGRN #CCHP—Capstone Green Energy…
NEW YORK–(BUSINESS WIRE)–#KBRA–KBRA releases its Equipment Loan & Lease indices for August 2022, providing monthly…
Orion Corporation NOTIFICATION 09.09.2022 at 18:30 ORION CORPORATION: ACQUISITION OF OWN SHARES 09.09.2022…
OSLO, Norway, Sept. 09, 2022 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage…
Follow-up data further demonstrate encouraging signs of clinical anti-tumor activity and a manageable safety and…
Immunocore presents promising initial Phase 1 data for first off-the-shelf TCR therapy targeting PRAME at…